{"id":"administration-of-l-tc","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1738872","moleculeType":"Small molecule","molecularWeight":"439.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"L-TC appears to be an immunotherapeutic agent developed by Institut de cancérologie Strasbourg Europe for cancer treatment. As a phase 3 candidate, it likely works through activation of T-cell mediated immunity against tumor-associated antigens, though the specific mechanism and target antigen(s) are not publicly detailed in standard pharmaceutical databases.","oneSentence":"L-TC is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:44:13.519Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication not publicly specified)"}]},"trialDetails":[{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT06476704","phase":"PHASE2","title":"Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas","status":"NOT_YET_RECRUITING","sponsor":"Institut de cancérologie Strasbourg Europe","startDate":"2025-06-01","conditions":"Sarcoma","enrollment":42},{"nctId":"NCT06477939","phase":"PHASE3","title":"Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients","status":"NOT_YET_RECRUITING","sponsor":"Institut de cancérologie Strasbourg Europe","startDate":"2025-01-01","conditions":"Glioblastoma","enrollment":554},{"nctId":"NCT05951816","phase":"PHASE1","title":"A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis","status":"UNKNOWN","sponsor":"University of Tennessee Graduate School of Medicine","startDate":"2023-07","conditions":"Systemic Amyloidosis","enrollment":35},{"nctId":"NCT02208869","phase":"","title":"Russian Familial Hypercholesterolemia Registry","status":"RECRUITING","sponsor":"Russian Cardiology Research and Production Center","startDate":"2014-01","conditions":"Familial Hypercholesterolemia","enrollment":1000},{"nctId":"NCT00882609","phase":"PHASE3","title":"F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets","status":"UNKNOWN","sponsor":"American College of Radiology - Image Metrix","startDate":"2009-01","conditions":"Bone Metastases","enrollment":550}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Administration of L-TC","genericName":"Administration of L-TC","companyName":"Institut de cancérologie Strasbourg Europe","companyId":"institut-de-canc-rologie-strasbourg-europe","modality":"Small molecule","firstApprovalDate":"","aiSummary":"L-TC is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells. Used for Cancer (specific indication not publicly specified).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}